Good morning—here’s your quick-hit, no-BS briefing on yesterday’s biggest catalysts and what to watch as markets wake up.

1) Biotech Breakout: FDA approval frenzy
Yesterday the FDA green-lit the first nasal-spray diuretic for heart, liver and kidney disease. That’s a real catalyst for vascular-care plays—on its heels, Krystal Biotech also scored an updated VYJUVEK label. Biotech skeptics better buckle up: when Washington clears the way, early movers can run hard.

2) Crypto Corner: Short squeeze incoming?
A high-roller trader’s up big on Dogecoin and still calls a “monster rally” to $1. At the same time, analysts warn Bitcoin is sniffing out a massive short squeeze before October rolls around—then a “long trap” could snap shut. If you’re in crypto, now’s the time to size your stakes and set your stops.

3) M&A Policy Showdown: Penalties vs. Growth
Capitol Hill is eyeing tougher merger-deal penalties—but a new critique argues slapping on more fees and hurdles won’t juice economic growth. Free-market heads will call BS: onerous M&A rules risk stifling the very innovation they’re supposed to protect. Keep an eye on any bills moving through committee—your favorite deal could be next in the crosshairs.

4) Corporate Clash: Patent infringement sparks suit
Nyxoah just filed a patent-infringement lawsuit against Inspire Medical Systems. Legal brawls like this can spark volatility for both acquirer hopes and target stock swings, so traders, note your entry and exit points.

What to Watch Today
• Earnings beat season? We’re watching retail and semis for early surprises.
• Bond yields vs. Bitcoin rotation—if yields tick up, risk assets could wobble.
• Any last-minute Washington policy scraps on M&A.

That’s your turbo-charged roundup. Don’t let the FOMO pass you by—stay sharp, stay nimble, and call out the BS when you see it. Have a killer trading day.